Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Phase II Chemotherapy with Anguidine for Pediatric and Adolescent Acute Lymphoblastic Leukemia in Relapse

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II Treatment Closed under 21 NCI POG-7810

Objectives

I.  Determine the clinical efficacy of anguidine (ANG) as indicated by the 
induction of partial or complete remission in pediatric and adolescent 
patients with acute lymphoblastic leukemia in relapse.
II.  Observe for factors predisposing to excessive myelosuppression and for 
other toxicities not observed during Phase I studies of this drug.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients under 21 years of age with 
lymphoid malignancy, disseminated in relapse, previously diagnosed as acute 
leukemia or lymphoma and who are either not eligible for protocols of higher 
priority or are resistant to standard forms of therapy.  Patients must have an 
M3 marrow with greater than 25% blasts and must not have had prior therapy 
with anguidine.

Expected Enrollment

40 to 50 patients will be entered in 2 to 2.5 years.  Protocol closed to all 
patients March 1981.

Outline

Nonrandomized study.
Single-agent Chemotherapy.  Anguidine, ANG, NSC-141537.

Trial Contact Information

Trial Lead Organizations

Pediatric Oncology Group

Teresa Vietti, MD, Protocol chair
Ph: 314-454-6209

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.